LONGEVA.

KPV: adverse events and evidence limits

Dalmasso and colleagues studied the tripeptide KPV (Lys-Pro-Val) in cell cultures and mice with colitis. Animals received it in drinking water: ten mice per group, assessed after eight days in the DSS model or 48 hours in the TNBS model. [1]

The study assessed intestinal inflammation, not clinical adverse-reaction frequencies. Human cell lines are not a human administration trial; these findings also do not establish safety for injected or topical KPV. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Clinical adverse-reaction frequencyCell cultures and mice with colitis (KPV in drinking water; ten mice per group, eight days in the DSS model or 48 hours in the TNBS model)The study assessed intestinal inflammation, not clinical adverse-reaction frequencies; these findings do not establish safety for injected or topical KPV[1]

References

  1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation https://doi.org/10.1053/j.gastro.2007.10.026.